imatinib has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 27 studies
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A pharmacokinetic study revealed that 18a had over 4 h of half-life and 24% bioavailability in rats." | 1.43 | Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le ( Chen, C; Hu, Z; Liang, X; Liu, J; Liu, Q; Liu, X; Lv, F; Qi, S; Qi, Z; Wang, A; Wang, B; Wang, L; Wang, W; Zhang, S; Zhao, Z; Zou, F, 2016) |
| " Further modification led to orally bioavailable dual MNK1 and 2 and BCR-ABL1 inhibitors 53 and 54, which are efficacious in a mouse xenograft model and also reduce the level of phosphorylated eukaryotic translation initiation factor 4E in the tumor tissues." | 1.43 | Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. ( Cherian, J; Chew, YS; Choong, ML; Ding, LJ; Guo, S; Hill, J; Ho, M; Jeyaraj, DA; Joy, JK; Keller, TH; Kwek, ZP; Lee, MA; Lim, S; Liu, B; Manoharan, V; Nacro, K; Ong, EH; Ong, ST; Pendharkar, V; Poh, ZY; Poulsen, A; Sangthongpitag, K; Wee, JL; Wong, YX; Yang, HY, 2016) |
| " It also displays good pharmacokinetics properties with an oral bioavailability of 35." | 1.42 | Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. ( Ding, K; Lu, X; Luo, J; Pan, X; Ren, X; Wang, D; Yu, R; Zhang, Z; Zhuang, X, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (11.11) | 29.6817 |
| 2010's | 19 (70.37) | 24.3611 |
| 2020's | 5 (18.52) | 2.80 |
| Authors | Studies |
|---|---|
| Adrián, FJ | 1 |
| Ding, Q | 1 |
| Sim, T | 1 |
| Velentza, A | 1 |
| Sloan, C | 1 |
| Liu, Y | 1 |
| Zhang, G | 1 |
| Hur, W | 1 |
| Ding, S | 1 |
| Manley, P | 1 |
| Mestan, J | 2 |
| Fabbro, D | 2 |
| Gray, NS | 1 |
| Silvestri, R | 1 |
| Marfè, G | 1 |
| Artico, M | 1 |
| La Regina, G | 1 |
| Lavecchia, A | 1 |
| Novellino, E | 1 |
| Morgante, E | 1 |
| Morgante, M | 1 |
| Di Stefano, C | 1 |
| Catalano, G | 1 |
| Filomeni, G | 1 |
| Abruzzese, E | 1 |
| Ciriolo, MR | 1 |
| Russo, MA | 1 |
| Amadori, S | 1 |
| Cirilli, R | 1 |
| La Torre, F | 1 |
| Sinibaldi Salimei, P | 1 |
| Bradner, JE | 1 |
| Xu, F | 1 |
| Shi, X | 1 |
| Li, S | 1 |
| Cui, J | 1 |
| Lu, Z | 1 |
| Jin, Y | 1 |
| Lin, Y | 1 |
| Pang, J | 1 |
| Pan, J | 1 |
| Crespan, E | 1 |
| Radi, M | 1 |
| Zanoli, S | 1 |
| Schenone, S | 1 |
| Botta, M | 1 |
| Maga, G | 1 |
| Manley, PW | 2 |
| Stiefl, N | 1 |
| Cowan-Jacob, SW | 2 |
| Kaufman, S | 1 |
| Wartmann, M | 1 |
| Wiesmann, M | 1 |
| Woodman, R | 1 |
| Gallagher, N | 1 |
| Li, Y | 2 |
| Shen, M | 1 |
| Zhang, Z | 3 |
| Luo, J | 2 |
| Pan, X | 3 |
| Lu, X | 2 |
| Long, H | 1 |
| Wen, D | 1 |
| Zhang, F | 1 |
| Leng, F | 1 |
| Tu, Z | 1 |
| Ren, X | 2 |
| Ding, K | 3 |
| Richters, A | 1 |
| Ketzer, J | 2 |
| Getlik, M | 1 |
| Grütter, C | 1 |
| Schneider, R | 1 |
| Heuckmann, JM | 1 |
| Heynck, S | 1 |
| Sos, ML | 1 |
| Gupta, A | 1 |
| Unger, A | 1 |
| Schultz-Fademrecht, C | 1 |
| Thomas, RK | 1 |
| Bauer, S | 2 |
| Rauh, D | 2 |
| Wang, D | 1 |
| Zhuang, X | 1 |
| Yu, R | 1 |
| Muthyala, R | 1 |
| Shin, WS | 1 |
| Xie, J | 1 |
| Sham, YY | 1 |
| Liu, X | 4 |
| Kung, A | 1 |
| Malinoski, B | 1 |
| Prakash, GK | 1 |
| Zhang, C | 1 |
| Liang, X | 1 |
| Wang, B | 2 |
| Zou, F | 1 |
| Wang, A | 2 |
| Qi, S | 1 |
| Chen, C | 2 |
| Zhao, Z | 1 |
| Wang, W | 4 |
| Qi, Z | 1 |
| Lv, F | 1 |
| Hu, Z | 2 |
| Wang, L | 2 |
| Zhang, S | 1 |
| Liu, Q | 3 |
| Liu, J | 2 |
| Sang, F | 1 |
| Ding, Y | 1 |
| Wang, J | 3 |
| Sun, B | 1 |
| Sun, J | 2 |
| Geng, Y | 1 |
| Wu, LL | 1 |
| Liu, JW | 1 |
| Bai, C | 1 |
| Yang, G | 1 |
| Zhang, Q | 2 |
| Li, LY | 1 |
| Chen, Y | 1 |
| Cherian, J | 1 |
| Nacro, K | 1 |
| Poh, ZY | 1 |
| Guo, S | 1 |
| Jeyaraj, DA | 1 |
| Wong, YX | 1 |
| Ho, M | 1 |
| Yang, HY | 1 |
| Joy, JK | 1 |
| Kwek, ZP | 1 |
| Liu, B | 1 |
| Wee, JL | 1 |
| Ong, EH | 1 |
| Choong, ML | 1 |
| Poulsen, A | 1 |
| Lee, MA | 1 |
| Pendharkar, V | 1 |
| Ding, LJ | 1 |
| Manoharan, V | 1 |
| Chew, YS | 1 |
| Sangthongpitag, K | 1 |
| Lim, S | 1 |
| Ong, ST | 1 |
| Hill, J | 1 |
| Keller, TH | 1 |
| Millet, A | 1 |
| Plaisant, M | 1 |
| Ronco, C | 1 |
| Cerezo, M | 1 |
| Abbe, P | 1 |
| Jaune, E | 1 |
| Cavazza, E | 1 |
| Rocchi, S | 1 |
| Benhida, R | 2 |
| Kaitsiotou, H | 1 |
| Keul, M | 1 |
| Hardick, J | 1 |
| Mühlenberg, T | 1 |
| Ehrt, C | 1 |
| Krüll, J | 1 |
| Medda, F | 1 |
| Koch, O | 1 |
| Giordanetto, F | 1 |
| Marzag, H | 1 |
| Zerhouni, M | 1 |
| Tachallait, H | 1 |
| Demange, L | 1 |
| Robert, G | 1 |
| Bougrin, K | 1 |
| Auberger, P | 1 |
| Schoepfer, J | 1 |
| Jahnke, W | 1 |
| Berellini, G | 1 |
| Buonamici, S | 1 |
| Cotesta, S | 1 |
| Dodd, S | 1 |
| Drueckes, P | 1 |
| Gabriel, T | 1 |
| Groell, JM | 1 |
| Grotzfeld, RM | 1 |
| Hassan, AQ | 1 |
| Henry, C | 1 |
| Iyer, V | 1 |
| Jones, D | 1 |
| Lombardo, F | 1 |
| Loo, A | 1 |
| Pellé, X | 1 |
| Rummel, G | 1 |
| Salem, B | 1 |
| Warmuth, M | 1 |
| Wylie, AA | 1 |
| Zoller, T | 1 |
| Marzinzik, AL | 1 |
| Furet, P | 1 |
| Sorrenti, V | 1 |
| Pittalà, V | 1 |
| Romeo, G | 1 |
| Amata, E | 1 |
| Dichiara, M | 1 |
| Marrazzo, A | 1 |
| Turnaturi, R | 1 |
| Prezzavento, O | 1 |
| Barbagallo, I | 1 |
| Vanella, L | 1 |
| Rescifina, A | 1 |
| Floresta, G | 1 |
| Tibullo, D | 1 |
| Di Raimondo, F | 1 |
| Intagliata, S | 1 |
| Salerno, L | 1 |
| Jiang, Z | 1 |
| Hu, C | 1 |
| Wu, H | 1 |
| Zhang, Y | 1 |
| Huang, T | 1 |
| Ren, T | 1 |
| Li, L | 1 |
| Xia, R | 1 |
| Ge, J | 1 |
| Li, W | 1 |
| Chu, J | 1 |
| Fan, T | 1 |
| Zhang, W | 1 |
| Yao, M | 1 |
| Ning, Z | 1 |
| Wang, M | 1 |
| Zhao, X | 1 |
| Wen, A | 1 |
| Liang, L | 1 |
| Sun, Y | 1 |
| Si, R | 1 |
| Fu, J | 1 |
| Zhang, J | 2 |
| Schoepf, AM | 1 |
| Salcher, S | 1 |
| Obexer, P | 1 |
| Gust, R | 1 |
| El-Damasy, AK | 1 |
| Jin, H | 1 |
| Seo, SH | 1 |
| Bang, EK | 1 |
| Keum, G | 1 |
| Pan, YL | 1 |
| Zeng, SX | 1 |
| Hao, RR | 1 |
| Liang, MH | 1 |
| Shen, ZR | 1 |
| Huang, WH | 1 |
| Pandrala, M | 1 |
| Bruyneel, AAN | 1 |
| Hnatiuk, AP | 1 |
| Mercola, M | 1 |
| Malhotra, SV | 1 |
| Marín-Rubio, JL | 1 |
| Peltier-Heap, RE | 1 |
| Dueñas, ME | 1 |
| Heunis, T | 1 |
| Dannoura, A | 1 |
| Inns, J | 1 |
| Scott, J | 1 |
| Simpson, AJ | 1 |
| Blair, HJ | 1 |
| Heidenreich, O | 1 |
| Allan, JM | 1 |
| Watt, JE | 1 |
| Martin, MP | 1 |
| Saxty, B | 1 |
| Trost, M | 1 |
1 review available for imatinib and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imat | 2022 |
26 other studies available for imatinib and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line; Cell Line, Transformed; Cell Proli | 2006 |
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Caspase 3; Caspase 8; Caspase 9; Ca | 2006 |
A pulse at the heart of targeted therapy.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Hum | 2009 |
Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Binding Sites; Cell | 2010 |
Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms.
Topics: Adenosine Triphosphate; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Kinetics; | 2010 |
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.
Topics: Benzamides; Cell Line; Cell Survival; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, | 2010 |
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Design; D | 2012 |
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.
Topics: Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Drug Resistance, Neoplasm; Humans; Leukemia, | 2013 |
Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.
Topics: Cell Proliferation; Fusion Proteins, bcr-abl; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mode | 2015 |
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crystallography, X-Ray; Dose-Response | 2015 |
Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase.
Topics: Alkynes; Animals; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Fusi | 2015 |
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell | 2016 |
Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resista | 2016 |
Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Chemistry Techniques, | 2016 |
Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screen | 2016 |
Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.
Topics: Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-A | 2017 |
Modular synthesis of new C-aryl-nucleosides and their anti-CML activity.
Topics: Antineoplastic Agents; Catalysis; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Me | 2018 |
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Topics: Allosteric Regulation; Animals; Dogs; Drug Discovery; Fusion Proteins, bcr-abl; Humans; Leukemia, My | 2018 |
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Cell Survival; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-a | 2018 |
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants includi
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferat | 2018 |
Design and synthesis of novel 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1,3,4-thiadiazol- 2-yl)urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway.
Topics: Antineoplastic Agents; Drug Design; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosph | 2019 |
Discovery of novel Bcr-Abl
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Proliferation; Drug Design; Fusion Proteins, | 2019 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistan | 2020 |
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
Topics: Amination; Antineoplastic Agents; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; | 2020 |
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous | 2022 |
A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia.
Topics: Cytokines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammat | 2022 |